DTX1: A Promising Drug Target / Biomarker (G1840)

Target Name: DTX1

NCBI ID: G1840

DTX1

DTX1: A Promising Drug Target / Biomarker

The drug target (DMT) is an important molecule in the development of new pharmaceuticals. It is a protein that is targeted by a drug to interact with its biological activity, leading to a desired response. One of the most promising drug targets in recent years is the protein known as DTX1.

DTX1: A Potential Drug Target

DTX1 is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is involved in the regulation of cell growth, differentiation, and survival. It has also been shown to play a role in the development and progression of various diseases, including cancer.

One of the most promising aspects of DTX1 is its potential as a drug target. Researchers have identified several potential drug targets for DTX1, including those that interact with its role in cell growth, differentiation, and survival. These targets include the K-src gene, the F-src gene, and the S-rc gene.

The K-src gene is a potential drug target for DTX1 because it is known to be involved in the regulation of cell growth and survival.DTX1 has been shown to interact with the K-src gene, which could lead to a desired response when the drug binds to the protein.

The F-src gene is another potential drug target for DTX1. It is known to be involved in the regulation of cell growth and survival, and has been shown to interact with DTX1. The F-src gene has been shown to play a role in the development and progression of various diseases, including cancer.

The S-rc gene is another potential drug target for DTX1. It is known to be involved in the regulation of cell survival and growth, and has been shown to interact with DTX1. The S-rc gene has also been shown to play a role in the development and progression of various diseases, including cancer.

Conclusion

DTX1 is a protein that is involved in the regulation of cell growth, differentiation, and survival. It has also been shown to play a role in the development and progression of various diseases, including cancer. As a result, it is a promising drug target for new pharmaceuticals.

Research has identified several potential drug targets for DTX1, including the K-src gene, the F-src gene, and the S-rc gene. These targets have the potential to lead to a desired response when the drug binds to the protein.

Further research is needed to understand the full potential of DTX1 as a drug target. Once it is fully understood, it can be used to develop new pharmaceuticals that target this protein and treat various diseases.

Protein Name: Deltex E3 Ubiquitin Ligase 1

Functions: Functions as a ubiquitin ligase protein in vivo, mediating ubiquitination and promoting degradation of MEKK1, suggesting that it may regulate the Notch pathway via some ubiquitin ligase activity (By similarity). Regulator of Notch signaling, a signaling pathway involved in cell-cell communications that regulates a broad spectrum of cell-fate determinations. Mainly acts as a positive regulator of Notch, but it also acts as a negative regulator, depending on the developmental and cell context. Mediates the antineural activity of Notch, possibly by inhibiting the transcriptional activation mediated by MATCH1. Involved in neurogenesis, lymphogenesis and myogenesis, and may also be involved in MZB (Marginal zone B) cell differentiation. Promotes B-cell development at the expense of T-cell development, suggesting that it can antagonize NOTCH1

The "DTX1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DTX1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets